SARDs are a heterogeneous group of disorders characterized by dysregulation of the immune system, that starts to turn against the body’s own tissues. Major SARDs include systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjögren’s syndrome. These diseases can affect multiple organs and share common symptoms such as fatigue, fever, joint pain and skin rash. Diagnosis relies on a combination of clinical assessment and specific autoantibody tests. Early diagnosis is crucial to initiate appropriate therapy and slow down disease progression.
Together with anti–Scl-70 and anti-centromere antibodies (ACA), anti–RNA polymerase III autoantibodies are among the main autoantibodies specific for systemic sclerosis (SSc). These antibodies are directed against the 11 kDa (RP11) or 155 kDa (RP155) subunits of RNA polymerase III, a nuclear enzyme involved in the transcription of non-coding RNAs.
Anti–RNA pol III antibodies are closely associated with diffuse cutaneous SSc and show a strong correlation with scleroderma renal crisis.
Thanks to their high diagnostic specificity, anti–RNA polymerase III antibodies are included in the 2013 ACR/EULAR classification criteria for systemic sclerosis, alongside ACA and anti–Scl-70.
Serum, EDTA plasma, heparin plasma, citrate plasma
Immunoblot
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.